# A PK Study GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers

> **NCT02072213** · PHASE1 · COMPLETED · sponsor: **GL Pharm Tech Corporation** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GL2702 GLARS-NF1
- **DRUG:** Omix Ocas

## Key facts

- **NCT ID:** NCT02072213
- **Lead sponsor:** GL Pharm Tech Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02072213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02072213, "A PK Study GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02072213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*